To retrospectively explore the association of prescribed Chinese medicine use with risk of CKD (chronic kidney disease) progression in patients with stage 3～4 CKD,and to provide evidence for the Chinese medicine treating CKD.Methods:According to whether received Chinese medicine treatment,patients with newly diagnosed stage 3～4 CKD in China-Japan Friendship Hospital from 2010 to 2017 were categorized into use or nonuse of prescribed Chinese medicine groups.These patients were followed until death,dialysis initiation,or till the end of 2017 after adjustment for confounding variables by using propensity score matching (PSM).The incidence rate of CKD progression and hazard ratio (HR) was investigated between the two groups in the end.Results:Overall,after adjustment for confounding variables by using PSM,a total of 524 patients developed CKD progression,including 275 in the non-use group with a incidence rate of 16/100 person-year,250 cases in the use group with a incidence rate of 13/100 person-year.The average time for CKD progression was 61.6±1.3 months in Chinese medicine group and 54.6±1.4 months in non-Chinese medicine group.The use group exhibited a significant 25% reduced CKD progression risk (HR 0.75,95% CI 0.63-0.89,P=0.001) compared with the nonuse group.Conclusion:Chinese medicine treatment is associated with reduced CKD progression risk in patients with stage 3～4 CKD.